Acadia Pharmaceuticals Stock News

Guggenheim lowered shares of ACADIA Pharmaceuticals (NASDAQ:ACAD) from a buy rating to a neutral rating in a research note released on Tuesday morning, PriceTargets.com reports. The firm currently has $28.00 price target on the biopharmaceutical companys stock. Several other analysts have also recently weighed in on ACAD. Oppenheimer boosted their price objective on shares of []

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) shares saw strong trading volume on Tuesday after Bank of America raised their price target on the stock from $28.00 to $32.00. Bank of America currently has a neutral rating on the stock. 66,969 shares changed hands during mid-day trading, a decline of 96% from the previous sessions volume of 1,727,407 [] The post ACADIA Pharmaceuticals (NASDAQ:ACAD) Sees Unusually-High Trading Volume After Analyst Upgrade appeared first on ETF Daily News .

RBC Capital raised the price target on Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) to $34 from $32 and kept an Outperform rating on the shares. Analyst Gregory Renza cites the Company''s confirmed intentions to resubmit the sNDA filing of pimavanserin in Alzheimer''s Disease Psychosis, with a "narrower though still robust opportunity" as the largest subtype of DRP. Renza adds that the development makes for a "catalyst-rich year" for Acadia. Related: Acadia Slims Nuplazid Label Expansion Application For Alzheimer''s Disease Psychosis . Stifel analyst Paul Matteis noted that the FDA has reiterated their previous … Full story available on Benzinga.com

After suffering rejection from the FDA in April , Acadia Pharmaceuticals Inc (NASDAQ: ACAD ) is making another bid to expand the scope of its Parkinson''s disease med Nuplazid. Acadia plans to resubmit its application for Nuplazid (pimavanserin) to treat hallucinations and delusions … Full story available on Benzinga.com

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

RBC Capital raised the price target on Acadia Pharmaceuticals Inc (NASDAQ:ACAD) to $34 from $32 and kept an Outperform rating on the shares.  Analyst Gregory Renza cites the Company's confirmed i

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus CytomX Mid-Phase Study Of ADC In Lung And Head & Neck Cancer Patients Show Lackluster Efficacy CytomX

ACADIA (ACAD) to resubmit sNDA for Nuplazid (pimavanserin) to the FDA for treating hallucinations and delusions associated with dementia focused on Alzheimer's disease psychosis. Shares rise.

Strs Ohio lifted its position in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 25.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 70,300 shares of the biopharmaceutical companys stock after acquiring an additional 14,400 shares during the quarter. Strs Ohios []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price objective boosted by The Goldman Sachs Group from $25.00 to $28.00 in a report issued on Wednesday morning, Analyst Price Targets reports. The Goldman Sachs Group currently has a neutral rating on the biopharmaceutical companys stock. Several other research firms also recently commented on ACAD. Cantor Fitzgerald lifted their [] The post ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target Raised to $28.00 at The Goldman Sachs Group appeared first on ETF Daily News .

Gemini Therapeutics (NASDAQ:GMTX) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, profitability, institutional ownership, valuation and earnings. Insider & Institutional Ownership 59.5% of Gemini Therapeutics shares are owned by institutional investors. Comparatively, 91.0% []

ACADIA Pharmaceuticals (NASDAQ:ACAD) had its price target increased by Mizuho from $24.00 to $26.00 in a research report released on Tuesday, The Fly reports. The brokerage currently has a neutral rating on the biopharmaceutical companys stock. A number of other equities analysts have also recently weighed in on ACAD. Morgan Stanley cut shares of ACADIA []

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) price on Wednesday, December 08, rose 2.16% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $21.78. A look at the stock’s price movement, the close in the last trading session was $21.32, moving within a range at $21.12 and $21.958. The beta value … ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD): The Metrics That Matter Right Now Read More »